This is Kineto Lab • Management


Attila Kigyós MSc. is the founder and Chief Executive Officer of KINETO Lab Research and Development Ltd. In addition to acting as the managing director of the corporation, Attila is a seasoned professional with more than 2 decades of experience in the field of IT, biotechnology and drug discovery screening.

Attila was selected as Chief Executive Officer based on his track record of leading Hungarian Biotech companies as executive manager, as well as strong executive and personal qualities.

He graduated at Eötvös Loránd University, Budapest in 1992 as a chemist. In his thesis he investigated different gas chromatography measurement methods for instrumental detection of volatile organic compounds released by plants.

In 1993 he participated in some intensive complementary courses to improve his faculty in developing new methods of gas chromatography measurement at the Eindhoven Technical University in The Netherlands.

From 1994 to 1997 he was a fellow and demonstrator in the Budapest University of Technology and Economics.

From 1998 he leads private companies as executive manager in IT and biotech fields as well.


József Tóvári, PhD, is the founder and Chief Scientific Officer of KINETO Lab Research and Development Ltd., head of the Departmant of Experimental Pharmacology, National Institute of Oncology, Budapest.

József Tóvari, PhD, has a strong scientific experience in the field of translational applied research and development in oncology. He is co-author of 76 scientific publications; his cumulative impact factor is >220. He has >1400 independent citations.

As Director of Research and Development for KINETO Lab, József Tóvari plays a cruical role in the design and management of the ongoing drug screening tests and services for companies at KINETO Lab.

After graduating as a biologist at the Eötvös Loránd University, Budapest in 1994, he continued his former research activities at the 1st Institute of Pathology and Experimental Cancer Research of the Semmelweis University of Medicine, Budapest. His main field of interest was the investigation of tumor metastasis including cell migration, invasion and interaction with extracellular matrices.

From the finishing of his PhD thesis in 1999 (title: Regulation of tumor cell – extracellular-matrix interaction in tumor metastasis process) he is working in the so called Metastasis Research Group in the National Institute of Oncology, Budapest and the National Korányi Institute of TB and Pulmonology, Budapest. He was visiting scientist in Finnland (University of Turku) and Switzerland (ETH) several times for various time periods with the help of joint research grants. He is member of three scientific associations (AACR, EACR, MOT) and supervises research works of five PhD and several undergraduate students from the faculty of natural science or medicine. His scientific work was awarded with Young Scientist Award (2000), György Miklós Award (2005) and Bolyai Scholarship (2001-2004) of the Hungarian Academy of Sciences, EJC-Pharmamar Grant for young scientist (2004) and AACR-NCI International Investigator Opportunity Grants (2008). Tóvári, PhD, holds lectures on cell motility and tumor angiogenesis for biology and physics students in Semmelweis University.


Mihály is a postdoctoral biologist researcher and project manager in KINETO Lab, focusing his work on Patient-derived xenograft models, primary tumor cell line establishment and antibody development, as well as in vivo experiment planning and supervision.

Mihály earned his MSc diploma in 2006 at Eötvös Loránd University, Budapest. After gaining practice in different cancer biology lab techniques in the National Korányi Institute of Pulmonology, he attended the Doctoral School of Pathological Sciences at Semmelweis University, under the supervision of József Tóvári (National Institute of Oncology) and Gergely Szakács (ELKH-TTK, Institute of enzymology). His theses, entitled ’Impact, and treatment possibility of chemotherapy resistance in cancer’ was submitted and PhD degree was awarded in 2020.

Mihály is author of 11 peer-reviewed articles, with the total impact factor of 70.9, and 183 citations (as of august, 2021). He attended to more than 15 scientific conferences, earning two prizes for best poster. Currently, he is also supervisor of a PhD student and an MSc student at the Department of Experimental Pharmacology of the National Institute of Oncology as a postdoctoral research fellow. His main area of interest involves tumor heterogeneity, patient-derived xenograft models, tumor hypoxia & metabolism, and chemotherapy resistance in cancer. He is also committed in the development and refinement of different microscopy and imaging techniques.


Ivan Randelovic, PhD is postdoctoral Biologist Researcher and Project Manager in KINETO Lab Research and Development Ltd, focusing on drug discovery screening and preclinical investigation and development of targeting cancer therapeutics. Ivan is also responsible for international relations. 

He graduated at Belgrade University, Belgrade, Serbia, on Faculty of Biology, on Department of Molecular Biology and Physiology, module of Experimental Biomedicine in 2014. In his Master thesis he investigated anticancer activity and mechanism of actions of neutral and cationic Iridium (III) complexes with various sets of ligands.

From 2015. as Marie Skłodowska-Curie PhD fellow he works on National Institute of Oncology, Budapest, Hungary, at the Department of Experimental Pharmacology, under supervision of Jozsef Tóvári, PhD, investigating the effect of small molecule peptide-drug conjugates for targeted drug delivery on tumor growth and metastasis in vitro and in vivo, in frame of Marie Skodowska-Curie Innovative Training Network (ITN-ETN) “Peptide-Drug Conjugates for Targeted Delivery in Tumor Therapy – MAGICBULLET” project; Grant no: 642004.

In 2017. he was on secondment in Translational Cancer Biology lab on Biomedicum at Helsinki University, Helsinki, Finland, and in 2018. in Molecular Biology lab at Preclinical Research Department at the Research Center of Italfarmaco SpA, Milan, Italy.

In 2021. Ivan obtained PhD degree on Semmelweis University, Budapest, Hungary, at the Doctoral School of Pathological Sciences, on Experimental Oncology program. Ivan is author of 13 articles published in international peer-reviewed journals with a total impact factor of 41.3 which were cited over 100 times. He represented his work on numerous scientific conferences, earning one prize for best poster. Ivan main area of interest involves target identification and the development of targeting cancer treatments.